Public beta© 2026 Adaptrex, LLC
Public beta© 2026 Adaptrex, LLC
Federal grant · cooperative agreement (b)
Sbir Phase Ii: a Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines -the Broader Impact/commercial Potential of This Small Business Innovation Research (SBIR) Phase Ii Project Is the Contribution to the Field of Conjugate Vaccines, Which Have Made Revolutionary and Tremendous Contributions to Public Health. When Successfully Developed, the Proposed Platform Will Be Available for Use by Biotechnology and Pharmaceutical Companies to Develop Next-generation Conjugate Vaccines Against a Wide Range of Antigens, Including Cancer and Emerging Infectious Diseases, for Improved Clinical Outcomes. in Addition to Vaccines, the Platform Offers an Excellent Starting Point for the Generation of Monoclonal Antibodies for Both Basic Scientific Research and Therapeutic Application. This Small Business Innovation Research Phase Ii Project Aims to Establish the Applicability, Robust Manufacturing and Characterization Protocols of a Proposed Mutant Bacteriophage Based Carrier Platform. This Work Will Establish Superior and Long-lasting Antibody Response Against Weakly Immunogenic Subunit Antigens, While Reducing the Anti-carrier Antibody Responses. This Project Will Advance the Demonstration of the Proposed Platform's Performance in Boosting the Immune Responses Against the Target Antigens, Relative to That of the Wild-type Bacteriophage and Commercially Available Carrier Proteins. This Award Reflects NSF'S Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.
Committed
$1.4 Million
Paid out
$1.4M
99%
Committed, not yet paid
$8.0K
<1%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…